Want to see AKTX full AI Analyst Report?
AKTX Stock Chart & Stats
$7.87
-$0.24(-2.76%)
At close: 4:00 PM EDT
$7.87
-$0.24(-2.76%)
Day’s Range― - ―
52-Week Range$3.02 - $33.60
Previous Close$8.46
Volume52.72K
Average Volume (3M)60.14K
Market Cap
$17.31M
Enterprise Value$11.29M
Total Cash (Recent Filing)$7.69M
Total Debt (Recent Filing)$693.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Apr 21, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1600.00
Shares Outstanding2,285,165
10 Day Avg. Volume44,336
30 Day Avg. Volume60,143
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$25.50Price Target Upside224.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-10.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery limited debt reduces fixed financial obligations and interest-related pressure while the company advances its development programs. This gives Akari more flexibility than a highly leveraged biotech, although continued losses still make preservation of capital important.
Focused Therapeutic StrategyA defined focus on autoimmune and inflammatory diseases, together with complement and immune-system targets, can concentrate research resources and organizational expertise. A focused development strategy may improve prioritization and support deeper capability in selected biological pathways over time.
Equity-linked Executive IncentivesLinking part of executive compensation to equity incentives and multi-year vesting can connect management rewards with shareholder outcomes and longer-term execution. The structure may support retention and alignment, though approval requirements and potential dilution remain relevant considerations.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Akari remains dependent on research progress and potential future financing rather than internally generated sales. Until a product reaches commercialization, the business has limited operating self-sufficiency and remains exposed to development and execution risk.
Widening Net LossesThe sharp increase in net losses indicates deteriorating earnings power while Akari continues funding development without revenue support. Persistent and widening losses can accelerate consumption of the capital base, reduce financial flexibility, and increase dependence on future funding.
Persistent Cash Burn And Shrinking EquitySustained negative operating and free cash flow means the company is not currently funding operations internally, while declining equity shows losses are eroding its capital base. Continued funding needs may require external financing and create meaningful dilution risk before revenue begins.
Akari Therapeutics News
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $3.02 and its highest was $33.60 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $17.31M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 21, 2027 which is in 182 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $1.04.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 2,285,165 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 7.714%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Stock 12 Month Forecast
Average Price Target
$25.50
▲(224.02% Upside)
Technical Analysis
Ownership Overview
17.16% Insiders
4.38% Other Institutional Investors
78.46% Public Companies and
Individual Investors